The companies Aurigene Discovery Technologies Limited and Pierre Fabre started a cooperation to design new cancer therapeutics in immune-oncology in 2014, which resulted in the structure of AUNP12 (1) (Figure 1), an immune checkpoint modulator targeting the PD-1/PD-L1 pathway [33,35]. This evidence concerns the gene PDCD1 and cancer.